Colchicine for COVID-19: real-time analysis of all 10 studies

Home

Database of all colchicine COVID-19 studies. Submit updates/corrections.


Jul 10	Late	Gaitán-Duarte et al., medRxiv, doi:10.1101/2021.07.06.21260085 (Preprint)	death, ↓19.0%, p=0.43	Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19
	Details RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, not showing statistically significant differences in outcomes. Improved results were seen with the combination of emtricitabine/tenofovir disoproxil + ..
Jul 10	Details Source PDF Late treatment study Late treatment study
	Gaitán-Duarte et al., medRxiv, doi:10.1101/2021.07.06.21260085 (Preprint)
	Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19
	RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, not showing statistically significant differences in outcomes. Improved results were seen with the combination of emtricitabine/tenofovir disoproxil + rosuvastatin + colchicine. NCT04359095. risk of death, 19.0% lower, RR 0.81, p = 0.43, treatment 22 of 153 (14.4%), control 28 of 161 (17.4%), adjusted, 28 days. risk of mechanical ventilation, 15.0% lower, RR 0.85, p = 0.15, treatment 27 of 136 (19.9%), control 27 of 140 (19.3%), adjusted. risk of ICU admission, 1.0% lower, RR 0.99, p = 0.97, treatment 19 of 113 (16.8%), control 18 of 114 (15.8%), adjusted. Gaitán-Duarte et al., 7/10/2021, Randomized Controlled Trial, Colombia, South America, preprint, 17 authors, this trial uses multiple treatments in the treatment arm (combined with rosuvastatin) - results of individual treatments may vary.
	Share Tweet Submit Corrections or Comments
May 18	Late	Horby et al., medRxiv, doi:10.1101/2021.05.18.21257267 (Preprint)	death, ↑1.0%, p=0.77	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
	Details RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, mean 9 days after symptom onset. Baseline oxygen requirements unknown (data is provided but combined with "none&qu..
May 18	Details Source PDF Late treatment study Late treatment study
	Horby et al., medRxiv, doi:10.1101/2021.05.18.21257267 (Preprint)
	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
	RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, mean 9 days after symptom onset. Baseline oxygen requirements unknown (data is provided but combined with "none"). ISRCTN 50189673. NCT04381936. risk of death, 1.0% higher, RR 1.01, p = 0.77, treatment 1173 of 5610 (20.9%), control 1190 of 5730 (20.8%). Horby et al., 5/18/2021, Randomized Controlled Trial, United Kingdom, Europe, preprint, 35 authors.
	Share Tweet Submit Corrections or Comments
Mar 14	Meta	Hariyanto et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488 (Peer Reviewed) (meta analysis)	meta-analysis	Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
	Details Meta analysis concluding that colchicine can reduce severity and mortality in COVID‐19 patients, mortality OR 0.43 [0.32-0.58].
Mar 14	Details Source PDF Meta Meta
	Hariyanto et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488 (Peer Reviewed) (meta analysis)
	Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
	Meta analysis concluding that colchicine can reduce severity and mortality in COVID‐19 patients, mortality OR 0.43 [0.32-0.58]. Hariyanto et al., 3/14/2021, peer-reviewed, 5 authors.
	Share Tweet Submit Corrections or Comments
Jan 27	Late	Tardif et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 (preprint 1/27) (Peer Reviewed)	death, ↓43.9%, p=0.30	Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
	Details RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment. NCT04322682.
Jan 27	Details Source PDF Late treatment study Late treatment study
	Tardif et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 (preprint 1/27) (Peer Reviewed)
	Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
	RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment. NCT04322682. risk of death, 43.9% lower, RR 0.56, p = 0.30, treatment 5 of 2235 (0.2%), control 9 of 2253 (0.4%), OR converted to RR. risk of mechanical ventilation, 46.8% lower, RR 0.53, p = 0.09, treatment 11 of 2235 (0.5%), control 21 of 2253 (0.9%), OR converted to RR. risk of hospitalization, 20.0% lower, RR 0.80, p = 0.07, treatment 101 of 2235 (4.5%), control 128 of 2253 (5.7%), OR converted to RR. Tardif et al., 1/27/2021, Double Blind Randomized Controlled Trial, Canada, North America, peer-reviewed, 44 authors.
	Share Tweet Submit Corrections or Comments
Nov 5 2020	Late	Rodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomes (Peer Reviewed)	death, ↓5.5%, p=0.87	Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study
	Details Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support. Confounding by indication likely.
Nov 5 2020	Details Source PDF Late treatment study Late treatment study
	Rodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomes (Peer Reviewed)
	Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study
	Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support. Confounding by indication likely. risk of death, 5.5% lower, RR 0.94, p = 0.87, treatment 16 of 52 (30.8%), control 85 of 261 (32.6%), unadjusted. Rodriguez-Nava et al., 11/5/2020, retrospective, USA, North America, peer-reviewed, median age 68.0, 8 authors.
	Share Tweet Submit Corrections or Comments
Oct 27 2020	Late	Sandhu et al., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954 (Peer Reviewed)	death, ↓41.7%, p=0.0006	A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
	Details Prospective cohort study of hospitalized patients in the USA, 34 treated with colchicine, showing lower mortality and intubation with treatment.
Oct 27 2020	Details Source PDF Late treatment study Late treatment study
	Sandhu et al., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954 (Peer Reviewed)
	A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
	Prospective cohort study of hospitalized patients in the USA, 34 treated with colchicine, showing lower mortality and intubation with treatment. risk of death, 41.7% lower, RR 0.58, p < 0.001, treatment 16 of 34 (47.1%), control 63 of 78 (80.8%). risk of mechanical ventilation, 52.9% lower, RR 0.47, p < 0.001, treatment 16 of 34 (47.1%), control 68 of 68 (100.0%). risk of no hospital discharge, 41.7% lower, RR 0.58, p < 0.001, treatment 16 of 34 (47.1%), control 63 of 78 (80.8%). hospitalization time, 4.5% lower, relative time 0.95, treatment 34, control 78. Sandhu et al., 10/27/2020, prospective, USA, North America, peer-reviewed, 4 authors.
	Share Tweet Submit Corrections or Comments
Oct 23 2020	Late	Pinzón et al., Research Square, doi:10.21203/rs.3.rs-94922/v1 (Preprint)	death, ↓34.5%, p=0.18	Clinical Outcome of Patients with COVID-19 Pneumonia Treated with Corticosteroids and Colchicine in Colombia
	Details Retrospective 301 pneumonia patients in Colombia showing lower mortality with colchicine treatment.
Oct 23 2020	Details Source PDF Late treatment study Late treatment study
	Pinzón et al., Research Square, doi:10.21203/rs.3.rs-94922/v1 (Preprint)
	Clinical Outcome of Patients with COVID-19 Pneumonia Treated with Corticosteroids and Colchicine in Colombia
	Retrospective 301 pneumonia patients in Colombia showing lower mortality with colchicine treatment. risk of death, 34.5% lower, RR 0.65, p = 0.18, treatment 14 of 145 (9.7%), control 23 of 156 (14.7%), OR converted to RR. Pinzón et al., 10/23/2020, retrospective, Colombia, South America, preprint, 9 authors.
	Share Tweet Submit Corrections or Comments
Sep 14 2020	Late	Scarsi et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217712 (Peer Reviewed)	death, ↓84.9%, p<0.0001	Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
	Details Retrospective 122 colchicine patients and 140 control patients in Italy, showing lower mortality with treatment.
Sep 14 2020	Details Source PDF Late treatment study Late treatment study
	Scarsi et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217712 (Peer Reviewed)
	Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
	Retrospective 122 colchicine patients and 140 control patients in Italy, showing lower mortality with treatment. risk of death, 84.9% lower, RR 0.15, p < 0.001, treatment 122, control 140. Scarsi et al., 9/14/2020, retrospective, Italy, Europe, peer-reviewed, 28 authors.
	Share Tweet Submit Corrections or Comments
Sep 14 2020	Late	Brunetti et al., J. Clin. Med., 9:9, 2961, doi:10.3390/jcm9092961 (Peer Reviewed)	death, ↓72.7%, p=0.03	Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
	Details PSM matched analysis from consecutive hospitalized patients, with 33 colchicine and 33 control matched patients, showing lower mortality with treatment.
Sep 14 2020	Details Source PDF Late treatment study Late treatment study
	Brunetti et al., J. Clin. Med., 9:9, 2961, doi:10.3390/jcm9092961 (Peer Reviewed)
	Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
	PSM matched analysis from consecutive hospitalized patients, with 33 colchicine and 33 control matched patients, showing lower mortality with treatment. risk of death, 72.7% lower, RR 0.27, p = 0.03, treatment 3 of 33 (9.1%), control 11 of 33 (33.3%), PSM. risk of no hospital discharge, 72.7% lower, RR 0.27, p = 0.03, treatment 3 of 33 (9.1%), control 11 of 33 (33.3%), PSM. Brunetti et al., 9/14/2020, retrospective, propensity score matching, USA, North America, peer-reviewed, 7 authors.
	Share Tweet Submit Corrections or Comments
Aug 12 2020	Late	Lopes et al., RMD Open, doi:10.1136/rmdopen-2020-001455 (preprint 8/12) (Peer Reviewed)	death, ↓80.0%, p=0.49	Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
	Details RCT with 36 colchicine and 36 control patients, showing reduced length of hospitalization and oxygen therapy with treatment.
Aug 12 2020	Details Source PDF Late treatment study Late treatment study
	Lopes et al., RMD Open, doi:10.1136/rmdopen-2020-001455 (preprint 8/12) (Peer Reviewed)
	Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
	RCT with 36 colchicine and 36 control patients, showing reduced length of hospitalization and oxygen therapy with treatment. risk of death, 80.0% lower, RR 0.20, p = 0.49, treatment 0 of 36 (0.0%), control 2 of 36 (5.6%), continuity correction due to zero event. risk of ICU admission, 50.0% lower, RR 0.50, p = 0.67, treatment 2 of 36 (5.6%), control 4 of 36 (11.1%). oxygen time, 38.5% lower, relative time 0.62, treatment 36, control 36. hospitalization time, 22.2% lower, relative time 0.78, treatment 36, control 361. Lopes et al., 8/12/2020, Double Blind Randomized Controlled Trial, Brazil, South America, peer-reviewed, 34 authors.
	Share Tweet Submit Corrections or Comments
Jun 24 2020	Late	Deftereos et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2020.13136 (Peer Reviewed)	death, ↓77.3%, p=0.19	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
	Details RCT with 55 patients treated with colchicine and 50 control patients, showing lower mortality and ventilation with treatment. NCT04326790.
Jun 24 2020	Details Source PDF Late treatment study Late treatment study
	Deftereos et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2020.13136 (Peer Reviewed)
	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
	RCT with 55 patients treated with colchicine and 50 control patients, showing lower mortality and ventilation with treatment. NCT04326790. risk of death, 77.3% lower, RR 0.23, p = 0.19, treatment 1 of 55 (1.8%), control 4 of 50 (8.0%). risk of mechanical ventilation, 81.8% lower, RR 0.18, p = 0.10, treatment 1 of 55 (1.8%), control 5 of 50 (10.0%). risk of clinical deterioration, 87.4% lower, RR 0.13, p = 0.05, treatment 1 of 55 (1.8%), control 7 of 50 (14.0%), OR converted to RR. Deftereos et al., 6/24/2020, Randomized Controlled Trial, Greece, Europe, peer-reviewed, 49 authors.
	Share Tweet Submit Corrections or Comments

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit